Paper41326809
Serotonin receptor 4 in the ventral CA3 regulates agomelatine-induced anxiolytic-like behaviors.
Liu XH and 6 others. Acta Pharmacol Sin, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Serotonin receptor 4 in the ventral CA3 regulates agomelatine-induced anxiolytic-like behaviors. Papers, record 41326809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41326809
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Serotonin receptor 4 in the ventral CA3 regulates agomelatine-induced anxiolytic-like behaviors.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acetamides | Major topic |
| Anti-Anxiety Agents | Major topic |
| Anxiety | Major topic |
| CA3 Region, Hippocampal | Major topic |
| Animals | |
| Male | |
| Mice | |
| Behavior, Animal | |
| Mice, Inbred C57BL | |
| Stress, Psychological | |
| Restraint, Physical | |
| Naphthalenes |
Source PubMed
References101
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36193171 | Quantifying the global burden of mental disorders and their economic value. | EClinicalMedicine | 2022 | https://conductscience.org/library/papers/36193171 | PubMed |
| 2 | 34979437 | Sleep and anxiety: From mechanisms to interventions. | Sleep Med Rev | 2022 | https://conductscience.org/library/papers/34979437 | PubMed |
| 3 | 33581801 | Anxiety disorders. | Lancet | 2021 | https://conductscience.org/library/papers/33581801 | PubMed |
| 4 | 33424664 | Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. | Front Psychiatry | 2020 | https://conductscience.org/library/papers/33424664 | PubMed |
| 5 | 29487083 | Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. | Pharmacol Rev | 2018 | https://conductscience.org/library/papers/29487083 | PubMed |
| 6 | 34210446 | Insomnia: Pharmacologic Treatment. | Clin Geriatr Med | 2021 | https://conductscience.org/library/papers/34210446 | PubMed |
| 7 | 28593281 | Simultaneous Antidepressant and Benzodiazepine New Use and Subsequent Long-term Benzodiazepine Use in Adults With Depression, United States, 2001-2014. | JAMA Psychiatry | 2017 | https://conductscience.org/library/papers/28593281 | PubMed |
| 8 | 33713641 | Diazepam effects on local cortical neural activity during sleep in mice. | Biochem Pharmacol | 2021 | https://conductscience.org/library/papers/33713641 | PubMed |
| 9 | 26514204 | MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. | Annu Rev Pharmacol Toxicol | 2016 | https://conductscience.org/library/papers/26514204 | PubMed |
| 10 | 34419186 | Circadian rhythm sleep-wake disturbances and depression in young people: implications for prevention and early intervention. | Lancet Psychiatry | 2021 | https://conductscience.org/library/papers/34419186 | PubMed |
| 11 | 24724693 | Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. | Br J Pharmacol | 2014 | https://conductscience.org/library/papers/24724693 | PubMed |
| 12 | 20577266 | Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. | Nat Rev Drug Discov | 2010 | https://conductscience.org/library/papers/20577266 | PubMed |
| 13 | 18794654 | Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. | J Clin Psychopharmacol | 2008 | https://conductscience.org/library/papers/18794654 | PubMed |
| 14 | 24766542 | Agomelatine in treating generalized anxiety disorder. | Expert Opin Investig Drugs | 2014 | https://conductscience.org/library/papers/24766542 | PubMed |
| 15 | 28730851 | Agomelatine for the treatment of generalized anxiety disorder. | Expert Opin Pharmacother | 2017 | https://conductscience.org/library/papers/28730851 | PubMed |
| 16 | 20950634 | Abnormal structure or function of the amygdala is a common component of neurodevelopmental disorders. | Neuropsychologia | 2011 | https://conductscience.org/library/papers/20950634 | PubMed |
| 17 | 16741211 | Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder. | Am J Psychiatry | 2006 | https://conductscience.org/library/papers/16741211 | PubMed |
| 18 | 24623781 | Circuit-wide structural and functional measures predict ventromedial prefrontal cortex fear generalization: implications for generalized anxiety disorder. | J Neurosci | 2014 | https://conductscience.org/library/papers/24623781 | PubMed |
| 19 | 34916083 | The impact of stress on the hippocampal spatial code. | Trends Neurosci | 2022 | https://conductscience.org/library/papers/34916083 | PubMed |
| 20 | 36680709 | Hippocampus: Molecular, Cellular, and Circuit Features in Anxiety. | Neurosci Bull | 2023 | https://conductscience.org/library/papers/36680709 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41326809
GET https://conductscience.org/api/papers/v1/41326809/references?page=2